DLBCL
Showing NaN - NaN of 11
Phase 1, NSCLC, SCLC Trial in United States (Oral MRT-2359)
Recruiting
- NSCLC
- +6 more
- Oral MRT-2359
-
Scottsdale, Arizona
- +7 more
Dec 20, 2022
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, DLBCL Trial in United States (KT-413)
Recruiting
- Non Hodgkin Lymphoma
- +3 more
-
Washington, District of Columbia
- +5 more
Nov 29, 2022
Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in United Kingdom, United States (AUTO3)
Active, not recruiting
- Diffuse Large B Cell Lymphoma
- +3 more
- AUTO3
-
Duarte, California
- +10 more
Oct 19, 2022
Large B-cell Lymphoma, DLBCL Trial in New York (89Zr-DFO-REGN3767, PET/CT)
Recruiting
- Large B-cell Lymphoma
- DLBCL
- 89Zr-DFO-REGN3767
- PET/CT
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Oct 3, 2022
DLBCL Trial in United States (MB-CART2019.1)
Recruiting
- DLBCL
- MB-CART2019.1
-
Gilbert, Arizona
- +14 more
Jun 17, 2022
B-ALL, DLBCL, B ALL Trial in New York (131-I Apamistamab, CAR T-cell)
Recruiting
- B-ALL
- +10 more
- 131-I Apamistamab
- CAR T-cell
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Mar 7, 2022